ESMO20: Phase III JAVELIN Bladder 100 study results released

Written by Rachel Jenkins, Future Science Group


The efficacy of avelumab, also known as BAVENCIO®, as a first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma has been described in a recent publication in The New England Journal of Medicine. The latest results also highlight exploratory biomarkers as well as patient-reported outcomes. The results from the Phase III JAVELIN Bladder 100 Study were published simultaneously with additional analyses being presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (19–21 October). In the study, avelumab plus best supportive care significantly extended overall survival (OS) compared with best supportive care alone in two primary populations...

To view this content, please register now for access

It's completely free